NCT06717347 2026-04-16
MK-2140-010
Merck Sharp & Dohme LLC
Phase 3 Recruiting
Clinical Trials
28 trialsNCT01804686 2026-04-13
CAN3001
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT03570892 2026-04-08
BELINDA
Novartis
Phase 3 Completed
NCT04231448 2026-04-08
DEB
Chipscreen Biosciences, Ltd.
Phase 3 Completed
NCT04628494 2026-04-08
EPCORE DLBCL-1
Genmab
Phase 3 Active not recruiting
NCT06508658 2026-04-08
EPCORE DLBCL-4
Genmab
Phase 3 Active not recruiting
NCT07226752 2026-04-08
A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China
Genmab
Phase 3 Active not recruiting
NCT04408638 2026-04-07
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04094311 2026-04-02
Study of Out of Specification for Tisagenlecleucel
Novartis
Phase 3 Recruiting
NCT04824092 2026-04-01
frontMIND
Incyte Corporation
Phase 3 Active not recruiting
NCT07409428 2026-04-01
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Hutchmed
Phase 3 Recruiting
NCT04529772 2026-03-31
ESCALADE
Acerta Pharma BV
Phase 3 Active not recruiting
NCT07493109 2026-03-25
Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP
The First Hospital of Jilin University
Phase 3 Recruiting
NCT04384484 2026-03-24
LOTIS 5
ADC Therapeutics S.A.
Phase 3 Active not recruiting
NCT04404283 2026-03-17
ECHELON-3
Seagen Inc.
Phase 3 Active not recruiting
NCT07188558 2026-03-04
PiNACLE-H2H
Lyell Immunopharma, Inc.
Phase 3 Recruiting
NCT04214444 2026-02-12
EVAPOR
University Hospital, Tours
Phase 3 Completed
NCT03274492 2026-02-06
POLARIX
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT06091865 2026-02-05
OLYMPIA-3
Regeneron Pharmaceuticals
Phase 3 Active not recruiting
NCT07348575 2026-01-16
A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma
Second Affiliated Hospital of Nanchang University
Phase 3 Enrolling by invitation
NCT06220032 2026-01-05
HO170DLBCL
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Recruiting
NCT04182204 2025-12-22
POLARGO
Hoffmann-La Roche
Phase 3 Completed
NCT05429268 2025-12-10
firmMIND
Incyte Corporation
Phase 3 Active not recruiting
NCT03391466 2025-12-01
ZUMA-7
Gilead Sciences
Phase 3 Completed
NCT06929624 2025-11-18
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT04833114 2025-09-30
Pola-R-ICE
GWT-TUD GmbH
Phase 3 Active not recruiting
NCT07011056 2025-09-19
A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 3 Recruiting
NCT00278408 2025-08-26
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Universität des Saarlandes
Phase 3 Completed